PharmaDerm
On February 21, 2008, Nycomed US Inc. successfully completed its acquisition of Bradley Pharmaceuticals Inc., a company focused on niche therapeutic markets in the United States. Bradley's success over the years has been largely due to its strength in identifying and developing new products through life cylce management. Now, with the addition of this successfuly pipelne strategy and combined product offerings, Nycomed is well-positioned as a leading specialty pharmaceutical player in the U.S. dermatological market.
PharmaDerm (formerly Doak Dermatologics), a subsidiary of Bradley Pharmaceuticals, has an 80-year history of providing quality skincare therapies to specialty physician audiences. Serving both the dermatology and podiatry communities, Doak brands provide symptomatic relief for a wide range of patients suffering from uncomfortable and often chronic skin and nail conditions, including acne, rosacea, actinic keratosis, psoriasis, seborrheic dermatitis and pruritic conditions such as
eczema and dermatitis.